By Kevin Stawicki ( December 5, 2019, 6:25 PM EST) -- Allergan told a New York federal judge that a group of Restasis buyers can't certify their class claims accusing the pharmaceutical giant of boosting profits by delaying a cheaper generic version of the dry-eye medication, saying some of the state laws from which the claims arise prohibit class actions....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.